Back to Library
Weight LossMetabolic Health

Tirzepatide + Cagrilintide

Synergistic blend of 'Twincretin' (GIP/GLP-1) and Amylin for maximum satiety.

Overview

This advanced research blend combines Tirzepatide (GIP/GLP-1) with Cagrilintide (Amylin analogue). While Tirzepatide optimizes metabolism and insulin sensitivity, Cagrilintide acts as a potent 'gastric brake,' physically slowing digestion and signaling deep satiety to the brain. Together, they attack obesity from three distinct angles: metabolic acceleration, appetite suppression, and mechanical fullness.

Chemical Information

IUPAC Name
Tirzepatide + Acylated Amylin Analogue
Sequence
Blend of Two Peptides
Molecular Mass
Mixture (N/A)
Formula
Mixture (N/A)
Chemical Structure not available

Mechanism of Action

Functions as a Triple-Pathway Synergist. 1. Tirzepatide (GIP/GLP-1): Enhances insulin secretion, reduces glucagon, and improves fat metabolism. It provides the 'metabolic engine.' 2. Cagrilintide (Amylin/Calcitonin): Activates amylin receptors in the hindbrain (Area Postrema) to induce a feeling of fullness and slows gastric emptying more potently than GLP-1s alone. Synergy: By combining a metabolic booster with a mechanical appetite suppressor, this stack mimics the natural hormonal flood of a large meal, leading to effortless caloric deficit.

Potential Research Fields

Severe ObesityType 2 DiabetesGastric EmptyingMulti-Agonist Therapy

Recent Research

This blend represents the cutting edge of 'combinatorial obesity therapy.' While pharmaceutical companies are racing to test *either* Tirzepatide *or* CagriSema, this research blend combines both concepts. Early data suggests that adding an Amylin analogue (Cagrilintide) to a GIP/GLP-1 backbone (Tirzepatide) creates a 'gastric lock' that physically prevents overeating, while the GIP component protects against the nausea typically seen with high-dose GLP-1s. It is hypothesized to offer the highest possible weight loss without surgery.

Bibliography / Scientific References

  • [1]CagriSema vs Tirzepatide
    Phase 3 Clinical Trial (Ongoing) • 2023-2025 - Investigating if Amylin + GLP-1 (CagriSema) beats Dual Agonist (Tirzepatide). This blend mimics that competition.
  • [2]Synergy of Amylin and GLP-1
    Translational Research • 2024 - Combination showed greater weight loss than either agent alone due to complementary brain signaling.

Related Peptides

Research
SLU-PP-332

Exercise mimetic for mitochondrial biogenesis and fat loss

Research
5-Amino-1MQ

NNMT inhibitor for fat loss and NAD+ restoration

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
10mg
Reconstitution
Reconstitute with 2ml Physiological Solution (Saline)
Dosage Options
20 Units
1x Week
Protocol for 10mg/2ml blend. (Conc: 5mg/ml. 20 units = 0.2ml = 1 mg total blend). Adjust as directed.
Schedule
1x Per Week
Timing: One specific day.
Duration
According to the Doctor
Potential Side Effects
Nausea
highvery common (due to dual gastric slowing)
Vomiting
moderatecommon (if overeating)
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.